GlassScriptPhysician profile
Jonathan Charles Bates
NPI 1336709237
$1,245.50
in general payments reported to CMS, 2019-2025
24 companies · $565 in 2025
The $565 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $116 · 2021: $13.87 · 2023: $57.48 · 2024: $493 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $144.71 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $104.77 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.70 | 2023-2025 | Jardiance |
| Abbvie INC. | $95.23 | 2024-2025 | |
| Boston Scientific Corporation | $93.85 | 2020 | |
| Novo Nordisk INC | $86.21 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Insulet Corporation | $73.33 | 2024 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $66.92 | 2024-2025 | |
| Lilly USA, LLC | $63.99 | 2023-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $59.16 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Cequr Corporation | $57.64 | 2024 | Cequr Simplicity |
| Amgen INC. | $44.78 | 2024 | Prolia, Evenity, Otezla |
| Sanofi-Aventis U.S. LLC | $42.01 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.64 | 2024-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $24.52 | 2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $22.40 | 2020 | |
| Ascensia Diabetes Care US INC. | $21.36 | 2025 | |
| Viatris Specialty LLC | $20.04 | 2025 | Yupelri |
| Seqirus USA INC | $17.82 | 2025 | Flucelvax, Fluad |
| Merck Sharp & Dohme LLC | $17.40 | 2024 | Vaxelis, Gardasil, Gardasil 9 |
| Ironshore Pharmaceuticals INC. | $17.04 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.50 | 2024 | |
| Glaxosmithkline, LLC. | $13.93 | 2024 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $11.55 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.